GlobeNewswire: MdxHealth (TM) Contains the last 10 of 14 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:16:49ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2016/10/04/876701/10165443/en/MDxHealth-Announces-Agreement-with-SouthGenetics-for-Distribution-of-SelectMDx-in-Central-South-America.html?f=22&fvtc=4&fvtv=20216MDxHealth Announces Agreement with SouthGenetics for Distribution of SelectMDx in Central/South America2016-10-04T05:04:27Z<![CDATA[IRVINE, Calif. and HERSTAL, Belgium, Oct. 4, 2016 (GLOBE NEWSWIRE) -- MDxHealth SA (Euronext: MDXH.BR) a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of urologic cancers, today announced that it has signed a distribution agreement for their SelectMDx(TM) for Prostate Cancer assay in select countries in Central and South America with SouthGenetics Inc.]]>https://www.globenewswire.com/news-release/2016/06/15/848600/10163503/en/MDxHealth-R-Grants-QIAGEN-Rights-to-MSP-Technology-for-QIAsure-Methylation-Test-for-Cervical-Cancer-Risk.html?f=22&fvtc=4&fvtv=20216MDxHealth (R): Grants QIAGEN Rights to MSP Technology for QIAsure Methylation Test for Cervical Cancer Risk2016-06-15T05:07:38Z<![CDATA[IRVINE, Calif. and HERSTAL, Belgium, June 15, 2016 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2015/09/18/769402/10149868/en/MDxHealth-R-Completion-of-the-acquisition-of-NovioGendix-New-share-capital-amount-and-new-number-of-shares.html?f=22&fvtc=4&fvtv=20216MDxHealth(R): Completion of the acquisition of NovioGendix - New share capital amount and new number of shares2015-09-18T15:32:47Z<![CDATA[IRVINE, Calif. and HERSTAL, Belgium, Sept. 18, 2015 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2015/05/18/736510/10134873/en/MDxHealth-s-ConfirmMDx-r-Predicts-Prostate-Cancer-Aggressiveness.html?f=22&fvtc=4&fvtv=20216MDxHealth's ConfirmMDx(r) Predicts Prostate Cancer Aggressiveness2015-05-18T06:04:54Z<![CDATA[IRVINE, Calif. and HERSTAL, Belgium, May 18, 2015 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2014/08/12/657855/10094254/en/MDxHealth-R-MDxHealth-Licensee-Exact-Sciences-Receives-FDA-Approval-for-its-Cologuard-Colon-Cancer-Screening-Assay.html?f=22&fvtc=4&fvtv=20216MDxHealth (R) : MDxHealth Licensee Exact Sciences Receives FDA Approval for its Cologuard Colon Cancer Screening Assay2014-08-12T07:04:54Z<![CDATA[The Centers for Medicare & Medicaid Services issues a preliminary decision to cover the cost of the test
IRVINE, Calif. , and HERSTAL, Belgium, Aug. 12, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the U.S. Food and Drug Administration's (FDA) has approved Exact Sciences' Cologuard]]>https://www.globenewswire.com/news-release/2014/07/22/652266/10090360/en/ConfirmMDx-Studies-Highlighted-by-Elsevier-Publisher-of-The-Journal-of-Urology-r.html?f=22&fvtc=4&fvtv=20216ConfirmMDx Studies Highlighted by Elsevier, Publisher of The Journal of Urology(r)2014-07-22T06:08:22Z<![CDATA[LIEGE, Belgium, July 22, 2014 (GLOBE NEWSWIRE) -- Underscores Importance of Recent Confirmatory Clinical Validation Results Leading to Medicare Reimbursement Milestone]]>https://www.globenewswire.com/news-release/2014/04/22/628355/10077615/en/MDxHealth-Signs-Agreement-with-Galaxy-Health-Network-PPO-Providing-Increased-Access-to-ConfirmMDx-for-Prostate-Cancer.html?f=22&fvtc=4&fvtv=20216MDxHealth Signs Agreement with Galaxy Health Network PPO Providing Increased Access to ConfirmMDx for Prostate Cancer2014-04-22T06:08:37Z<![CDATA[Agreement Increases Access with Additional 3.5 Million Covered Lives]]>https://www.globenewswire.com/news-release/2014/04/02/623616/10075112/en/MDxHealth-and-LI-PATH-Announce-Marketing-Agreement-for-ConfirmMDx-for-Prostate-Cancer.html?f=22&fvtc=4&fvtv=20216MDxHealth and LI PATH Announce Marketing Agreement for ConfirmMDx for Prostate Cancer2014-04-02T06:10:47Z<![CDATA[IRVINE, Calif. and HERSTAL, Belgium, April 2, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into a co-marketing agreement with LI PATH (Long Island Pathology, Inc.) to promote MDxHealth's ConfirmMDx]]>https://www.globenewswire.com/news-release/2014/02/27/613757/10070346/en/MDxHealth-Reports-Fourth-Quarter-and-Fiscal-Year-2013-Results.html?f=22&fvtc=4&fvtv=20216MDxHealth Reports Fourth Quarter and Fiscal Year 2013 Results2014-02-27T07:04:39Z<![CDATA[Sharp increase in ConfirmMDx test volume with 10% penetration among U.S. urology community and revenue of $7.6 million in 2013 IRVINE, Calif. and HERSTAL, Belgium, Feb. 27, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results for the fourth quarter and the fiscal year ended December 31, 2013. This year the company has changed its reporting currency to U.S. Dollars, while keeping its functional currency in Euros.]]>https://www.globenewswire.com/news-release/2014/02/12/609475/10068090/en/MDxHealth-s-ConfirmMDx-R-for-Prostate-Cancer-Epigenetic-Test-Correctly-Identifies-Prostate-Cancer-Missed-in-Five-Previous-Biopsies.html?f=22&fvtc=4&fvtv=20216MDxHealth's ConfirmMDx(R) for Prostate Cancer Epigenetic Test Correctly Identifies Prostate Cancer Missed in Five Previous Biopsies2014-02-12T07:09:02Z<![CDATA[Multidisciplinary Case Study Published in The Journal of OncoPathology IRVINE, Calif. and HERSTAL, Belgium, Feb. 12, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the ConfirmMDx]]>